1. 2015 Cavitation of lung metastases induced by regorafenib in patients with colorectal carcinoma: Data from the phase III CORRECT study. (September 2015) Authors: Ricotta, R.; Verrioli, A.; Ghezzi, S.; Grothey, A.; Cremolini, C.; Argiles, G.; Adenis, A.; Ychou, M.; Barone, C.; Bouchet, O.; Humblet, Y.; Mineur, L.; Sobrero, A.; Peeters, M.; Van Cutsem, E.; Porcu, L.; Amatu, A.; Sartore-Bianchi, A.; Vanzulli, A.; Siena, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S333 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2070 Is PREDIST-based response assessment an accurate selection tool for organ-preserving strategies after chemoradiotherapy for rectal cancer?. (September 2015) Authors: Joye, I.; Debucquoy, A.; Haustermans, K.; Wolthuis, A.; D'Hoore, A.; Van Cutsem, E.; Vandecaveye, V.; Sagaert, X.; Palmans, S.; Deroose, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S352 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2108 Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. (September 2015) Authors: Van Cutsem, E.; Obermannova, R.; Bodoky, G.; Prausová, J.; García-Carbonero, R.; Ciuleanu, T.; Alfonso, P Garcia; Portnoy, D.; Cohn, A.; Yamazaki, K.; Clingan, P; Yoshino, T.; Polikoff, J.; Lonardi, S.; Macarulla, T.; Yang, L.; Nasroulah, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S365 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2120 Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI + cetuximab in the CRYSTAL study. (September 2015) Authors: Yamaguchi, K.; Ando, M.; Ooki, A.; Beier, F.; Guenther, S.; Hohnhorst, P Von; Van Cutsem, E. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S370 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 2123 Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer. (September 2015) Authors: Cohn, A. Lee; Yoshino, T.; Obermannova, R.; Bodoky, G.; Prausova, J.; Garcia-Carbonero, R.; Ciuleanu, T. Eliade; Garcia-Alfonso, P.; Portnoy, D.C.; Van Cutsem, E.; Yamazaki, K.; Clingan, P.R.; Polikoff, J.; Lonardi, S.; Gao, L.; Yang, L.; Chang, S.C.; Ferry, D.; Nasroulah, F.; Tabernero, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S372 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 2139 CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy. (September 2015) Authors: Van Cutsem, E.; Ciardiello, F.; Seitz, J.F.; Hofheinz, R.D.; Verma, U.; Garcia-Carbonero, R.; Grothey, A.; Miriyala, A.; Kalmus, J.; Shapiro, J.; Falcone, A.; Zaniboni, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S378 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 2141 Safety outcomes from 3 observational or phase 4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC). (September 2015) Authors: Hurwitz, H.; Zafar, Y.; Kozloff, M.; Hubbard, J.; Van Cutsem, E.; Bennouna, J.; Arnold, D.; Bekaii-Saab, T.; Srock, S.; Revil, C.; Fish, S.; Barue, V.; Grothey, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S379 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 2143 Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study. (September 2015) Authors: Ciardiello, F.; Falcone, A.; Cascinu, S.; Sobrero, A.; Boni, C.; Barone, C.; Luppi, G.; Maiello, E.; Siena, S.; Zagonel, V.; Carteni, G.; Constanzo, F. Di; Bartolomeo, M. Di; Santoro, A.; Russo, A.; Moscovici, M.; Van Cutsem, E.; Zaniboni, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S380 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 2150 Low rates of hospitalizations with TAS-102 in the European (EU) subregion of the Phase 3 RECOURSE trial in patients (pts) with metastatic colorectal cancer (mCRC). (September 2015) Authors: Falcone, A.; Garcia-Carbonero, R.; Tabernero, J.; Sobrero, A.; Peeters, M.; Zaniboni, A.; Hochster, H.; Lenz, H.J.; Tran, B.; Yamaguchi, K.; Muro, K.; Denda, T.; Tsuji, Y.; Wahba, M.; Benedetti, F.; Ohtsu, A.; Mayer, R.J.; Van Cutsem, E. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S383 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC). (September 2015) Authors: Shinozaki, E.; Laurent, S.; Gravalos, C.; Benavides, M.; Munoz, F. Longo; Mizuguchi, H.; Wahba, M.; Ychou, M.; Ciardiello, F.; Siena, S.; Yamaguchi, K.; Muro, K.; Denda, T.; Tsuji, Y; Loehrer, P; Lenz, H.J.; Tebbutt, N.; Mayer, R.J.; Van Cutsem, E.; Ohtsu, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S383 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗